The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | C | Cardiovascular system | |
2 | C02 | Antihypertensives | |
3 | C02A | Antiadrenergic agents, centrally acting | |
4 | C02AC | Imidazoline receptor agonists |
Code | Title | |
---|---|---|
C02AC01 | Clonidine | |
C02AC02 | Guanfacine | |
C02AC04 | Tolonidine | |
C02AC05 | Moxonidine | |
C02AC06 | Rilmenidine |
Active Ingredient | Description | |
---|---|---|
Clonidine |
Clonidine has been shown to have both central and peripheral sites of action. With long-term treatment clonidine reduces the responsiveness of peripheral vessels to vasoconstrictor and vasodilator substances and to sympathetic nerve stimulation. Early in treatment, however, blood pressure reduction is associated with a central reduction of sympathetic outflow and increased vagal tone. |
|
Guanfacine |
Guanfacine is a selective alpha2A-adrenergic receptor agonist in that it has 15-20 times higher affinity for this receptor subtype than for the alpha2B or alpha2C subtypes. Guanfacine is a non-stimulant. The mode of action of guanfacine in ADHD is not fully established. |
|
Moxonidine |
Moxonidine has been shown to bind selectively to the I1-imidazoline receptors in the brain stem. These imidazoline-sensitive receptors are concentrated in the rostral ventrolateral medulla, an area which is of crucial importance for central control of the peripheral sympathetic nervous system. The result of this effect on the I1-imidazoline receptors has been apparent in reduced activity in the sympathetic nerves. (demonstrated for cardiac, splanchnic and renal sympathetic nerves). |
Title | Information Source | Document Type | |
---|---|---|---|
CATAPRES Solution for injection | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
CATAPRES Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
HYPERIUM Tablet | Medicines Authority (MT) | MPI, EU: SmPC | |
INTUNIV Prolonged-release tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
MOXONIDINE Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
ONYDA Extended-release oral suspension | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
PHYSIOTENS Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |